

(19)



(11)

**EP 4 494 636 A3**

(12)

**EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:  
**30.04.2025 Bulletin 2025/18**

(51) International Patent Classification (IPC):  
**A61K 9/14** (2006.01) **A61K 9/20** (2006.01)  
**A61K 31/4184** (2006.01) **A61P 35/00** (2006.01)

(43) Date of publication A2:  
**22.01.2025 Bulletin 2025/04**

(52) Cooperative Patent Classification (CPC):  
**A61K 31/4184; A61K 9/141; A61K 9/2054;**  
**A61P 35/00**

(21) Application number: **24202355.4**

(22) Date of filing: **03.12.2015**

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**  
Designated Extension States:  
**BA ME**  
Designated Validation States:  
**MA MD**

(71) Applicant: **Aragon Pharmaceuticals, Inc.**  
**Los Angeles, CA 90024 (US)**

(72) Inventors:  
• **HESTER, Dennis Martin**  
**San Diego, California, 92130 (US)**  
• **VAUGHN, Jason Michael**  
**High Point, North Carolina, 27265 (US)**

(30) Priority: **05.12.2014 EP 14196594**

(74) Representative: **Carpmaels & Ransford LLP**  
**One Southampton Row**  
**London WC1B 5HA (GB)**


(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
**15817641.2 / 3 226 841**

**(54) ANTICANCER COMPOSITIONS**

(57) The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naïve metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resis-

tant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509 and HPMCAS. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509 and HPMCAS and optionally subsequently milling said melt-extruded mixture. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by spray drying a mixture comprising ARN-509 and HPMCAS in a suitable solvent.

Figure 1: Powder XRD. Diffraction patterns of ARN-509 Form B.



Processed by Luminess, 75001 PARIS (FR)



## EUROPEAN SEARCH REPORT

Application Number

EP 24 20 2355

## DOCUMENTS CONSIDERED TO BE RELEVANT

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X,P	WO 2015/118015 A1 (LEK PHARMACEUTICALS [SI]) 13 August 2015 (2015-08-13)  * page 4 - page 10 * -----	1,2,4,5, 7-10, 12-14, 16,18	INV. A61K9/14 A61K9/20 A61K31/4184 A61P35/00
A,P	WO 2015/023710 A1 (TOKAI PHARMACEUTICALS INC [US]; NJAR VINCENT [US]; ZOUBEIDI AMINA [CA]) 19 February 2015 (2015-02-19) * paragraphs [0146], [0147], [0149], [0158] * * paragraphs [0092], [0133], [0134], [0137] * -----	1-18	
X	WO 2013/152342 A1 (OSI PHARMACEUTICALS LLC [US]) 10 October 2013 (2013-10-10) * page 6, line 28 - page 7, line 2 * * page 7, lines 32-39 * * page 8, lines 16-20 * -----	3,6,11, 15,17	
			TECHNICAL FIELDS SEARCHED (IPC)
			A61K
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	
The Hague		14 March 2025	
		Examiner	
		Weiss, Marie-France	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P04C01)

# ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 24 20 2355

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-03-2025

10

15

20

25

30

35

40

45

50

55

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2015118015 A1	13-08-2015	AU 2015215000 A1	15-09-2016
		CA 2940984 A1	13-08-2015
		CN 106102716 A	09-11-2016
		CN 112402360 A	26-02-2021
		EA 201691568 A1	30-01-2017
		EA 201891397 A1	29-03-2019
		EP 3102183 A1	14-12-2016
		JP 6666254 B2	13-03-2020
		JP 6934932 B2	15-09-2021
		JP 2017507928 A	23-03-2017
		JP 2020090505 A	11-06-2020
		KR 20160113294 A	28-09-2016
		KR 20200015830 A	12-02-2020
		US 2016346207 A1	01-12-2016
		US 2020163882 A1	28-05-2020
		WO 2015118015 A1	13-08-2015
-----			
WO 2015023710 A1	19-02-2015	AU 2014306698 A1	28-01-2016
		BR 112016002970 A2	12-09-2017
		CA 2920317 A1	19-02-2015
		CN 105636594 A	01-06-2016
		EP 3033088 A1	22-06-2016
		JP 2016528252 A	15-09-2016
		KR 20160058774 A	25-05-2016
		RU 2016104643 A	19-09-2017
		SG 11201600525X A	26-02-2016
		US 2015374721 A1	31-12-2015
		US 2016038511 A1	11-02-2016
		WO 2015023710 A1	19-02-2015
-----			
WO 2013152342 A1	10-10-2013	NONE	
-----			

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82